Abstract 936P
Background
There are over 500,000 survivors of head and neck cancer (HNC) in the United States. While chronic pain is a common symptom across all cancer sites, we hypothesized it is more prevalent in HNC compared with other cancer sites, due to tumor location, treatment modality and functional impairment associated with HNC.
Methods
To compare self-reported chronic pain prevalence, we built a retrospective cohort of adult survivors with a history of cancer, using the National Health Interview Survey (NHIS) from 2010 to 2021. Study participants were grouped into HNC (n = 354) vs. other cancer survivors (n = 24,055), based on self-report of a previous cancer diagnosis. We estimated weighted prevalence rates of chronic pain in our sample, and in the final models, we estimated odds of reporting chronic pain while adjusting for sociodemographic (race, insurance, education, income, employment and smoking history) and clinical (depression, and self-rated health status) factors, using multivariate logistic regression analysis.
Results
Weighted, age-adjusted prevalence of chronic pain was significantly higher in HNC compared to other cancers (HNC = 45.5%, 95% CI: 42.6%, 48.5% vs. other cancers = 31.6%, 95% CI: 29.9%, 33.2%; p = 0.02). After adjusting for clinical and sociodemographic covariates, odds of reporting chronic pain remained significantly higher among HNC survivors compared to other cancers (aOR=1.34, 95% CI: 1.03, 1.75). Other factors associated with self-reported chronic pain included having depression (aOR=2.03, 95% CI: 1.90, 2.17), ≥ 65 years (aOR=0.74, 95% CI: 0.68, 0.80), being Hispanic (aOR=0.70, 95% CI:0.59, 0.83) compared to a non-Hispanic White, having private insurance (aOR=0.74, 95% CI: 0.69, 0.80), and education below high school level (aOR=1.39, 95% CI: 1.24, 1.56).
Conclusions
Chronic pain is highly prevalent among survivors of HNC, with almost 50% reporting chronic pain. Additionally, survivors of HNC are 34 percent more likely to report chronic pain compared to non-HNC survivors. Our findings highlight the burden of chronic pain in cancer, and the pressing need for effective pain management especially in HNC survivors.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
938TiP - Phase II TROPHY-IO-HN study of pembrolizumab ±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Amanda Psyrri
Session: Poster session 03
941TiP - A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Saira Khalique
Session: Poster session 03
942TiP - A randomized controlled clinical trial of neoadjuvant immunochemotherapy vs up-front surgery in patients with locally advanced resectable oral squamous cell carcinoma (Tophill trial)
Presenter: Laiping Zhong
Session: Poster session 03
Resources:
Abstract
945TiP - JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Presenter: Jean-Pascal Machiels
Session: Poster session 03
1002P - A phase Ia study of the myeloid-derived suppressor cell modulator HF1K16 in refractory and metastatic cancer patients: Preliminary efficacy and safety
Presenter: Ruofan Huang
Session: Poster session 03
1003P - A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)
Presenter: Mathilde Beaufils
Session: Poster session 03